ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults
Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults
1 other identifier
interventional
79
1 country
2
Brief Summary
Project:EVO is a video-game based intervention that targets neural networks associated with cognitive control. The same networks have been implicated in poor treatment response in middle and older aged adults suffering from major depression. Related work has demonstrated that healthy older adults show significant improvement in cognitive control. In a very small sample of older adults suffering from depression (n=12), we found similar improvements in selective attention and working memory after 4 weeks of intervention, along with improvements in mood comparable to participants receiving an evidence-based psychotherapy. The intent of this proposal is to first determine if at least 2/3 of participants who use Project:EVO for four weeks demonstrate significant improvements in the function of these neural networks, and if improvements are observed, to conduct a second study to see if changes in neural network functions are associated with changes in mood. If we show that Project:EVO improves neural function and mood to a greater degree than a placebo cognitive training game, we will be in a position to move onto the next phase of study, which is to demonstrate the intervention's efficacy in a much larger sample of adults with depression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2019
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 1, 2016
CompletedFirst Posted
Study publicly available on registry
September 7, 2016
CompletedStudy Start
First participant enrolled
January 2, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 20, 2022
CompletedDecember 21, 2022
December 1, 2022
3.1 years
September 1, 2016
December 19, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
CCN Function (Circuitry and Performance)
\- Assess pre-post treatment change in activation (percent signal Δ) during the stroop/flanker test
8 weeks
CCN Function (Self-Report- Disability)
\- Pre-post self-report assessment of disability via WHO Disability Assessment Scale (36-item)
8 weeks
CCN Function (Self-Report- Depressive Symptoms)
\- Pre-post self-report assessment of depressive symptoms via Hamilton Depression Rating Scale (24-item)
8 weeks
Study Arms (2)
Control Arm (R 33)
PLACEBO COMPARATORa mobile 3D video game to be used as placebo.
Intervention Arm (R 33)
EXPERIMENTALa mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
Interventions
a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
Eligibility Criteria
You may qualify if:
- (1) Age 45 to 75; (2) unipolar, nonpsychotic major depression (by SCID, DSM-V), (3) Hamilton Depression Rating Scale \> 20; (4) off antidepressants or have been on a stable dose for 12 weeks and do not intend to change dose in the next 5 weeks, (5) capacity to consent; (6) ability to participate in MRI.
You may not qualify if:
- \) Intent or plan to attempt suicide in the near future; 2) history or presence of psychiatric diagnoses other than unipolar, non-psychotic major depression or generalized anxiety disorder; 3) use of psychotropic drugs or cholinesterase inhibitors other than mild doses of benzodiazepines 4) dementia or MCI (please see Human Subjects). Participants with an MMSE score falling 1 SD below the mean score for their age and education will be excluded as well.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Washingtonlead
- Weill Medical College of Cornell Universitycollaborator
- University of California, San Franciscocollaborator
Study Sites (2)
Weill-Cornell Medical Center
White Plains, New York, 10605, United States
University of Washington Department of Psychiatry and Behavioral Sciences
Seattle, Washington, 98195, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Patricia A Arean, PhD
University of Washington
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Psychiatry and Behavioral Sciences
Study Record Dates
First Submitted
September 1, 2016
First Posted
September 7, 2016
Study Start
January 2, 2019
Primary Completion
January 20, 2022
Study Completion
January 20, 2022
Last Updated
December 21, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will share
We will make de-identified data available to all parties interested.